Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727065 | 0.86 | MAPT (0.49) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL22557782 | 0.84 | KDM4E (0.46) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL1078510 | 0.84 | MAPT (0.49) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL5989774 | 0.83 | CYP2C9 (0.47) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL30746848 | 0.83 | MEN1 (0.43) | MAPTALOX15ALDH1A1CXCR2KDM4E | |
| SCHEMBL6727129 | 0.83 | MAPT (0.46) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL1040683 | 0.83 | MEN1 (0.43) | MAPTALOX15ALDH1A1CXCR2KDM4E | |
| SCHEMBL1077964 | 0.82 | PTGS2 (0.45) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL24455292 | 0.80 | ALOX15 (0.43) | MAPTALOX15ALDH1A1HSD17B10CFTR | |
| SCHEMBL5740305 | 0.80 | MEN1 (0.41) | MAPTALOX15ALDH1A1CXCR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473271-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240199580-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11851419-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4247804-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-7576114-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7425637-B2 | mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent | ARRAY BIOPHARMA INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007002157-A2 | PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002092-A1 | SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MAPT 3314/4885ALOX15 3030/4885ALDH1A1 3556/4885 |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAPT 4838/4885ALOX15 3175/4885ALDH1A1 1438/4885 |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | REN, BRAF, CDK4 | MAPT 3124/4885ALOX15 2918/4885ALDH1A1 1456/4885 |
| US-11851419-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885ALOX15 3030/4885ALDH1A1 3556/4885 |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAPT 4838/4885ALOX15 3175/4885ALDH1A1 1438/4885 |
| US-12473271-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885ALOX15 3030/4885ALDH1A1 3556/4885 |
| US-20240199580-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MAPT 3314/4885ALOX15 3030/4885ALDH1A1 3556/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAPT 4844/4885ALOX15 3206/4885ALDH1A1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.